Dex Liquidating Co. designs and manufactures proprietary stapling devices for minimally invasive surgical procedures in the United States, Japan, Germany, and internationally. It primarily develops and commercializes MicroCutter 5/80, a cartridge-based micro stapler device used by for thoracic, pediatric, bariatric, colorectal, and general surgeons. The company also designs, manufactures, and markets automated anastomotic systems for use by cardiac surgeons to perform coronary bypass surgery. It provides C-Port xA Distal Anastomosis System to perform an end-to-side distal anastomosis by attaching the end of a bypass graft to a coronary artery downstream of an occlusion or narrowing; C-Port Flex A anastomosis system to enable automated anastomoses to be performed as part of minimally invasive and robot-facilitated CABG procedures; and PAS-Port Proximal anastomosis system to perform an end-to-side proximal anastomosis between a saphenous vein and the aorta. In addition, the company licenses its intellectual property in the robotics field in diagnostic or therapeutic medical procedures. Dex Liquidating Co. markets its products through its direct sales force, as well as through independent sales representatives and distributors. The company was formerly known as Dextera Surgical Inc. and changed its name to Dex Liquidating Co. in April 2018. Dex Liquidating Co. was founded in 1997 and is based in San Mateo, California. On December 11, 2017, Dextera Surgical Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.